Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUUST trial of ustekinumab plus budesonide versus ustekinumab alone in Crohn's disease
jRCTs021200013Completed
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ustekinumab and budesonide in Crohn's disease (2 arms). Primary endpoint: Clinical remission rate at 8 weeks. Started Feb 2018; status: completed.
02
Drugs
ustekinumabbudesonide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCTs021200013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021200013.